NASDAQ OMX

Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results

Dela

Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017

Vitaros Drug-Device Human Factor Studies Underway

Operations Funded Through the Third Quarter of 2018

Conference Call / Webcast Today, May 11, 2017 at 4:30 p.m. ET

SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2017 and provided a corporate update on its priorities for the year.

"In the first quarter of this year, we continued to execute on our strategy by creating a more focused and capital efficient organization with the potential to deliver on multiple regulatory, business development and commercial milestones over the next twelve months," stated Richard W. Pascoe, Chief Executive Officer. "More recently we have significantly improved our financial outlook through a combination of fundraising, venture debt retirement, and expense reduction resulting in a balance sheet that is expected to fund our current operating plan through the third quarter of 2018.  Finally, we remain on track to re-submit the Vitaros NDA in the third quarter of this year with an anticipated approval decision in the first half of 2018."

Recent Highlights

Apricus continues to execute on its corporate strategy as highlighted below:

Vitaros(TM) (alprostadil)

  • Continued implementation of the U.S. regulatory approval strategy to address issues raised by the FDA in the original Vitaros NDA submission.  Specifically, all safety, chemistry, manufacturing and control (CMC) related issues raised in the original Non-Approvable Letter will be addressed in the re-submission.  In addition, the FDA has determined that the Vitaros product will be considered a drug-device combination product and as such, Apricus has confirmed the necessary device engineering and compliance requirements, including human factor testing, and those studies are currently underway in accordance with the applicable FDA guidance; and
  • Sold Vitaros ex-US rights and assets to Ferring International in March 2017 for approximately $12.7 million, including an $11.5 million upfront payment received at closing, a $700,000 inventory payment received last month, and $500,000 in transition services that Apricus is eligible to receive over two quarters, subject to certain limitations, and eliminated certain future ex-US Vitaros liabilities.

RayVa(TM) (alprostadil)

  • Initiated a partnering process to secure a global or regional RayVa partnership prior to initiating a Phase 2b clinical study; and
  • Continued to refine the clinical trial protocol and clinical trial material formulation needed to initiate a Phase 2b study.

Corporate/Financial

  • Closed on an underwritten public offering of common stock and warrants in April 2017 for gross proceeds of approximately $7.0 million;
  • Paid $6.6 million to retire our remaining venture debt with Oxford Finance and Silicon Valley Bank;
  • Reduced our monthly cash burn to approximately $500,000; and
  • Regained compliance with all criteria for continued listing on The NASDAQ Capital Market, including the minimum stockholders' equity requirement.

First Quarter Financial Results

Net income for the quarter ended March 31, 2017 was $8.1 million, or basic earnings per share of $1.04, compared to a net loss of $2.5 million, or basic loss per share of $0.46, for the first quarter of 2016. Net income during the first quarter of 2017 was primarily due to the $11.8 million gain recorded in Q1 2017 for the sale of our ex-U.S. Vitaros rights and assets to Ferring. For both periods presented, financial statement activity related to our ex-U.S. Vitaros business has been presented as discontinued operations.

As of April 26, 2017, the Company's cash totaled $10.6 million, compared to $2.1 million as of December 31, 2016.

Conference Call Details

Apricus will host a live conference call and webcast today at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a corporate update. To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 18008306. The live and archived audio webcast can be accessed through the Investors Relations' section of the Company's website at www.apricusbio.com. Please log in approximately five to ten minutes before the event to ensure a timely connection. The archived webcast will be available for 30 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus' ability to transition its ex-U.S. assets and rights related to Vitaros to Ferring and receive the transition services payments from Ferring; the timing of regulatory submission and approval of Vitaros in the United States, if any; Apricus' development and partnering plans for RayVa; Apricus' plans to reduce operating expenses and achieve profitability, including projected 2017 cost savings; and Apricus' strategic objectives. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the risk that Apricus fails to provide the transition services as required by the transition services agreement with Ferring; the risk that the cost and other negative effects related to the reduction of Apricus' workforce may be greater than anticipated; the risk that Apricus may not realize the benefits expected from cost control measures; competition in the erectile dysfunction market and other markets in which Apricus operates; Apricus' ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus' ability to further develop Vitaros, such as delivery device improvements; Apricus' ability to carry out further clinical studies for Vitaros, if required, as well as the timing and success of the results of such studies; the failure to remain in compliance with NASDAQ continued listing requirements which could result in Apricus' common stock being delisted from the exchange; Apricus' ability to retain and attract key personnel; Apricus' ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus' ability to secure a  strategic partner for RayVa; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

(Financial Information to Follow)


 
Selected Financial Information
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
 
    Three Months Ended
 March 31,
    2017   2016
Operating expense        
Research and development   $ (412 )   $ (2,602 )
General and administrative   (1,441 )   (2,224 )
Total other (expense) income   (1,551 )   2,312  
    Loss from continuing operations   (3,404 )   (2,514 )
    Income from discontinued operations   11,477     9  
Net income (loss)   $ 8,073     $ (2,505 )
         
Earnings (loss) per share        
Basic   $ 1.04     $ (0.46 )
Diluted   $ 1.04     $ (0.95 )
Weighted average common shares outstanding        
Basic   7,737     5,505  
Diluted   7,737     5,602  

 
Condensed Consolidated Balance Sheets
(In thousands)
 
    March 31,
 2017
  December 31,
 2016
    (Unaudited)    
Assets        
Cash   $ 3,762     $ 2,087  
Other current assets   181     177  
Property and equipment, net   142     164  
Other long term assets   65     60  
Assets of discontinued operations   $ 1,203     $ 2,212  
Total assets   $ 5,353     $ 4,700  
         
Liabilities and stockholders' equity (deficit)        
Current liabilities   $ 1,768     $ 2,536  
Notes payable, net   -     6,650  
Current liabilities of discontinued operations   822     2,108  
Warrant liabilities   1,854     846  
Other long term liabilities   67     76  
Stockholders' equity (deficit)   842     (7,516 )
Total liabilities and stockholders' equity (deficit)   $ 5,353     $ 4,700  

CONTACT:    

Matthew Beck
mbeck@troutgroup.com
The Trout Group
(646) 378-2933




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Hattrick för LeoVegas vid EGR Nordics Awards 201822.1.2018 08:00Pressmeddelande

Vid EGR Nordics Awards lyfts de mest framgångsrika och innovativa spelbolagen fram. I hård konkurrens vann LeoVegas tre utmärkelser, "Nordics Operator of the Year", "Casino Operator of the Year" och "Sports Betting Operator of the Year" "Vi är väldigt glada över att ha vunnit Casino Operator- och Sports Betting Operator of the Year eftersom det är dessa två spelkategorier som definierar, och är vår produkt. Att dessutom bli utsedd till Nordics Operator of the Year är helt fantastiskt! Att få dessa utmärkelser är ett kvitto på att vi är ett extremt duktigt team på LeoVegas som ständigt levererar. Det visar också att vi är det ledande GameTech bolaget som verkligen leder vägen inom Norden", säger Gustaf Hagman, Group CEO. Nordics Operator of the Year LeoVegas vann utmärkelsen Nordics Operator of the Year för att LeoVegas har under det senaste året varit en drivkraft för innovation inom alla delar av bolagets verksamhet och tydligt lyckats särskilja sig från konkurrenterna genom en mix av

Hat-trick for LeoVegas at EGR Nordics Awards 201822.1.2018 08:00Pressmeddelande

The most successful and innovative gaming companies are noticed at the EGR Nordic Awards. In fierce competition, LeoVegas won three awards, "Nordics Operator of the Year", "Casino Operator of the Year" and "Sports Betting Operator of the Year". "We are extremely pleased to have won the Casino Operator and the Sports Betting Operator awards as these are the two main categories that define our product. Being declared as the Nordics Operator of the Year is really outstanding! To receive these awards is a receipt that we are an extremely talented team at LeoVegas that is constantly delivering. It also shows that we are the GameTech company that is leading the way within the Nordic region," says Gustaf Hagman, Group CEO. Nordics Operator of the Year LeoVegas won the award for the Nordics Operator of the Year because LeoVegas has been the driving force for innovation in all parts of the company and clearly distinguished from its competitors through a mix of high growth, innovation and strong

Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February22.1.2018 08:00Pressmeddelande

Press Release 22 January 2018 Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced that Immunicum leadership will present the Company and attend several upcoming industry and scientific conferences in January and February. ASCO/SITC - Clinical Immuno-Oncology Symposium Date: January 25 - 27, 2018 Venue: San Francisco Marriott Marquis, San Francisco, California Aktiedagen Lund Date: January 30, 2018 Presentation: Tuesday, January 30, 10:15 am Central European Time Venue: Medicon Village, Hörsalen Scheelevägen 2, Lund, Sweden Please register to attend at https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-30-januari Cholangiocarcinoma Foundation Annual Conference Date: January 31 - February 2, 2018 Presentation: Poster Session - Thursday, February 1, 7:00 - 9:00 pm Mountai

Immunicum AB (publ) meddelar kommande presentationer och deltagande i konferenser under januari och februari22.1.2018 08:00Pressmeddelande

Pressmeddelande 22 januari 2018 Immunicum AB (publ) meddelar kommande presentationer och deltagande i konferenser under januari och februari Immunicum AB (IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att Immunicums ledning kommer att presentera bolaget och delta under flera kommande branschkonferenser och forskningskonferenser under januari och februari. ASCO/SITC - Clinical Immuno-Oncology Symposium Datum: 25-27 januari 2018 Plats: San Francisco Marriott Marquis, San Francisco, Kalifornien, USA Aktiedagen Lund Datum: 30 januari 2018 Presentation: tisdag den 30 januari, 10:15 CET Plats: Medicon Village, Hörsalen Scheelevägen 2, Lund För att delta, registrera dig här https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-30-januari Cholangiocarcinoma Foundation Annual Conference Datum: 31 januari-2 februari 2018 Presentation: Poster Session: torsdag den 1 februari, kl. 19:00-21:00 Mountain Standard

SD-WAN Market Leader Aryaka Names Claudio Perugini Senior Vice President of Global Channels22.1.2018 06:00Pressmeddelande

SAN MATEO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today that networking industry veteran Claudio Perugini has joined the company's leadership team as Senior Vice President of Global Channels. In his new role, Perugini will lead and further scale Aryaka's global partner program as the company continues to grow rapidly and expand its market footprint in 2018. "Aryaka's channel partners have played an essential role in establishing the company as the market leader in the global SD-WAN space," said Perugini. "Our technology is a game-changer for the channel community as we offer global enterprises a next-generation alternative to legacy network technologies. As the Senior Vice President of Global Channels, my key focus areas will be recruitment, further scaling the channel organization, enhancing the structure of the Aryaka Global Partner Program, and improving partner enablement." Perugini has more than 30 years of channel and sale

Ant Financial Hosts Technology Conference in Silicon Valley20.1.2018 06:39Pressmeddelande

Conference featured global fintech leaders and showcased Ant Financial's capabilities across blockchain, AI, security, IoT and computing SANTA CLARA, Calif., Jan. 20, 2018 (GLOBE NEWSWIRE) -- Ant Financial today hosted the Ant Technology Exploration Conference (ATEC) in Silicon Valley, bringing together global partners and technology leaders to explore new innovations and technologies that further Ant Financial's mission of bringing the world equal opportunities. This was the first ATEC held outside of China, following the inaugural ATEC held in Hangzhou in October 2017. The conference featured a diverse range of speakers from academia and industry to better explore the future of fintech, including Turing Award winner and MIT Professor Silvio Micali; Partner and Director of blockchain-based global payment platform Ripple, Emi Yoshikawa; founder of prediction market Bodhi, Xiahong Lin; and Director of JPMorgan Chase's digital channels, Umar Farooq, among others. Ant Financial's Vice Pre

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum